*Fund Houses Recommendations* UBS on *Aarti Ind:* Upgrade to Buy on Company, raise target price at Rs 625/Sh versus Rs 615/Sh (Positive) Nomura on *Fortis:* Maintain Buy on Company, raise target price at Rs 820/Sh versus Rs 700/Sh (Positive) JP Morgan on *IDFC First:* Upgrade to Neutral on Company, raise target price at Rs 63/Sh (Positive) Macquarie on *LIC:* Maintain Outperform on Company, target price at Rs 1215/Sh (Positive) CLSA on *Auro Pharma:* Maintain Outperform on Company, target price at 1400/Sh (Positive) GS on *Auro Pharma:* Maintain Buy on Company, target price at Rs 1275/Sh (Positive) JP Morgan on *NMDC:* Maintain Underweight on Company, target price at Rs 56/Sh (Neutral) Citi on *Info Edge:* Maintain Buy on Company, cut target price at Rs 1685/Sh (Neutral) Nomura on *Info Edge:* Maintain Buy on Company, cut target price at Rs 1670/Sh (Neutral) GS on *LIC:* Maintain Neutral on Company, target price at Rs 880/ (Neutral) MOSL on *LIC:* Maintain Buy on Company, target price at Rs 1050/ (Neutral) UBS on *Auro Pharma:* Maintain Sell on Company, target price at Rs 1200/Sh (Neutral) Citi on *Auro Pharma:* Maintain Sell on Company, target price at Rs 1100/Sh (Neutral) CLSA on *TTK Prestige:* Maintain Hold on Company, cut target price at Rs 620/Sh (Neutral) Jefferies on *Afcons:* Maintain Buy on Company, target price at Rs 580/Sh (Neutral) Nomura on *KEC Int:* Maintain Buy on Company, target price at Rs 985/Sh (Neutral) JP Morgan on *Indusind Bank:* Downgrade to Reduce on Bank, cut target price at Rs 660/Sh versus Rs 770/Sh (Negative) JP Morgan on *Federal Bank:* Downgrade to Neutral on Bank, target price at Rs 210/Sh (Negative)